Skip to main content
 

Main menu

  • Home
  • Content
    • Current Issue
    • Editor's Commentary
    • Archives
    • Most-Read Papers of 2022
  • Authors
    • Author Guidelines
    • Submit a Manuscript
  • Reviewers
    • Reviewer Information
    • Create Reviewer Account
    • Reviewer Guidelines: Original Research
    • Reviewer Guidelines: Reviews
    • Appreciation of Reviewers
  • CRCE
    • Through the Journal
    • JournalCasts
    • AARC University
    • PowerPoint Template
  • Open Forum
    • 2023 Call for Abstracts
    • 2022 Abstracts
    • Previous Open Forums
  • Podcast
    • English
    • Español
    • Portugûes
    • 国语
  • Videos
    • Video Abstracts
    • Author Interviews
    • Highlighted Articles
    • The Journal

User menu

  • Subscribe
  • My alerts
  • Log in

Search

  • Advanced search
American Association for Respiratory Care
  • Subscribe
  • My alerts
  • Log in
American Association for Respiratory Care

Advanced Search

  • Home
  • Content
    • Current Issue
    • Editor's Commentary
    • Archives
    • Most-Read Papers of 2022
  • Authors
    • Author Guidelines
    • Submit a Manuscript
  • Reviewers
    • Reviewer Information
    • Create Reviewer Account
    • Reviewer Guidelines: Original Research
    • Reviewer Guidelines: Reviews
    • Appreciation of Reviewers
  • CRCE
    • Through the Journal
    • JournalCasts
    • AARC University
    • PowerPoint Template
  • Open Forum
    • 2023 Call for Abstracts
    • 2022 Abstracts
    • Previous Open Forums
  • Podcast
    • English
    • Español
    • Portugûes
    • 国语
  • Videos
    • Video Abstracts
    • Author Interviews
    • Highlighted Articles
    • The Journal
  • Twitter
  • Facebook
  • YouTube
Research ArticleOriginal Research

Increased Asymmetric Dimethylarginine and Ischemia-Modified Albumin Levels in Obstructive Sleep Apnea

Aysel Sunnetcioglu, Selvi Asker, Hamit Hakan Alp and Hulya Gunbatar
Respiratory Care August 2016, 61 (8) 1038-1043; DOI: https://doi.org/10.4187/respcare.04472
Aysel Sunnetcioglu
Department of Chest Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Selvi Asker
Department of Chest Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hamit Hakan Alp
Department of Biochemistry, Medical Faculty, Yuzuncu Yil University, Van, Turkey.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hulya Gunbatar
Department of Chest Diseases
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
Loading

Abstract

BACKGROUND: Asymmetric dimethylarginine and ischemia-modified albumin are new biomarkers that are used for evaluation of ischemia and oxidative stress. The present study aimed to investigate whether serum levels of asymmetric dimethylarginine and ischemia-modified albumin are altered in subjects with obstructive sleep apnea (OSA).

METHODS: A cross-sectional, clinical study was implemented on data derived from 79 subjects who underwent polysomnography. Cases were allocated into 3 groups with respect to polysomnography results: Group 1 consisted of 22 subjects without apnea, whereas Group 2 comprised 29 subjects with mild to moderate OSA, and Group 3 included 28 subjects with severe OSA. These 3 groups were compared in terms of demographic datas and polysomnographic parameters, serum levels of asymmetric dimethylarginine and ischemia-modified albumin.

RESULTS: Serum levels of ischemia-modified albumin were significantly higher in Groups 2 and 3 (P = .001). Mean SpO2 of Group 3 was notably lower than that of Groups 1 and 2 (P < .001), whereas times for SpO2 <90% were statistically significantly different from each other in all 3 groups (P < .001). Serum levels of asymmetric dimethylarginine in Group 3 were notably higher than those in Group 1 (P = .027). Levels of ischemia-modified albumin were correlated positively with AHI and time SpO2 <90% values (P = .008 and P < .001, respectively).

CONCLUSIONS: Ischemia-modified albumin and asymmetric dimethylarginine were significantly higher in subjects with OSA. Furthermore, ischemia-modified albumin was independently associated with severity of OSA defined by AHI and severity of oxygen desaturation.

  • obstructive sleep apnea
  • asymmetric dimethylarginine
  • ischemia modified albumin

Introduction

Obstructive sleep apnea (OSA) is a common disorder characterized by recurrent episodes of upper airway obstruction during sleep.1 Due to intermittent hypoxia, chronic sympathetic activation, and systemic inflammation seen in conjunction with OSA, the risk of cardiovascular morbidity was found to be increased.2–8 However, the underlying pathophysiology for the link between OSA and cardiovascular disorders has not been precisely elucidated.4,6,7

Asymmetric dimethylarginine is the endogenous inhibitor of nitric-oxide synthase. Since asymmetric dimethylarginine inhibits nitric oxide synthase activity, decreased nitric oxide levels result in impaired endothelial function and decreased vasodilatation. Asymmetric dimethylarginine is now known to be a mediator molecule of the adverse vascular effects of many other factors and markers of cardiovascular risk. Asymmetric dimethylarginine levels increase under hypoxic conditions.9 Increased asymmetric dimethylarginine concentration indicates endothelial dysfunction and is an important parameter in determining cardiovascular morbidity and mortality.

Ischemia-modified albumin has been regarded as a new and emerging marker of ischemia and oxidative stress.2 During ischemia/reperfusion, the structure of the amino terminus of albumin is changed in a way that causes the decrease of its cobalt binding capacity, leading to the formation of an ischemia-modified albumin.10 It increases within minutes after the onset of ischemia, and its levels remain elevated for several hours and return to normal within 24 h.11

Intermittent hypoxia, hypoxia/reoxygenation sequences, and high oxidative stress in patients with OSA are the major events causing endothelial dysfunction. Vascular tone and endothelial function are 2 important factors that may be involved in the association of OSA with cardiovascular morbidity. Impairment of endothelium-dependent vasodilatation had been reflected as changes in levels of nitric oxide and asymmetric dimethylarginine in OSA.8,12 Similarly, one study13 implied that serum ischemia-modified albumin, an indicator of oxidative stress and inflammation, may serve as a biomarker in OSA. Our hypothesis was that these levels would be elevated. The aim of the present study was to investigate the alteration of serum levels of asymmetric dimethylarginine and ischemia-modified albumin in OSA and to test their correlation with demographic and polysomnographic indices.

QUICK LOOK

Current knowledge

Intermittent hypoxia, hypoxia/reoxygenation sequences, and high oxidative stress in patients with obstructive sleep apnea (OSA) are the major events causing endothelial dysfunction. Asymmetric dimethylarginine and ischemia-modified albumin are produced in response to ischemic stresses, such as hypoxia. However, asymmetric dimethylarginine and ischemia-modified albumin in OSA causing endothelial dysfunction has not been precisely evaluated.

What this paper contributes to our knowledge

Ischemia-modified albumin and asymmetric dimethylarginine were significantly higher in subjects with OSA. Furthermore, ischemia-modified albumin levels were associated with severity of OSA defined by apnea-hypopnea index. Serum levels of ischemia-modified albumin and asymmetric dimethylarginine may be altered in OSA, reflecting the deterioration of vascular endothelial function.

Methods

Study Design

This cross-sectional, clinical study was conducted in the Pulmonology Department at the Faculty of Medicine at Yuzuncu Yil University Hospital (Van, Turkey) between January and June 2014. The study was approved by the institutional review board. Seventy-nine subjects with a complaint of excessive daytime sleepiness and snoring were recruited for polysomnography. OSA was defined as apnea-hypopnea index (AHI) ≥5 events/h. Cases with AHI < 5 constituted Group 1 (n = 22), whereas cases with AHI values between 5 and 30 were termed as mild to moderate OSA (Group 2, n = 29), and subjects with an AHI of ≥30 (severe OSA) constituted Group 3 (n = 28).

Previous treatment for sleep disorder (oral appliances or positive airway pressure before the sleep study), history of uvulopharyngeal or orthognathic surgery, any neurological deficit or neuromuscular diseases, and diagnosis of another sleep disorder, including central apnea, were exclusion criteria for the present study. In addition, patients with hypertension, diabetes mellitus, hyperlipidemia, COPD, interstitial lung disease, or asthma were also excluded from the study.

Sleep Study

Diagnosis of OSA was accomplished with respect to the results of overnight polysomnography by means of a digital 16-channel Embla (Medcare, Reykjavik, Iceland) polygraph performed at our sleep laboratory. Generally accepted definitions and scoring methods were utilized, and diagnosis of OSA was established in the presence of chest and abdominal paradoxical movement during apnea events or flow limitation on the nasal pressure signals.1

Biochemical Assays

Blood samples were obtained early in the morning after an overnight fasting period. Peripheral venipuncture was made from brachial veins, and blood samples were collected into vacutainer tubes. Serum samples were centrifuged at 3,000 rpm for 5 min and were maintained at −80°C until analysis.

Reduced cobalt-to-albumin binding capacity (ischemia-modified albumin level) was measured using the rapid and colorimetric method developed by Bar-Or et al14 Briefly, 200 μL of subject serum was transferred into glass tubes, and 50 μL of 0.1% CoCl2 × 6H2O (Sigma-Aldrich, St. Louis, Missouri) was added. After gentle shaking, the mixture was incubated for 10 min to ensure sufficient cobalt-albumin binding. Then 50 μL of 1.5 mg/mL dithiothreitol (Sigma-Aldrich) was added as a coloring agent. After 2 min, 1 mL of 0.9% NaCl was added to halt the binding between the cobalt and albumin. A blank was prepared for every specimen. At the dithiothreitol addition step, 50 μL of distilled water was used instead of 50 μL of 1.5 mg/mL dithiothreitol to obtain a blank without dithiothreitol. The absorbances were recorded at 470 nm with a UV1601 spectrophotometer (Shimadzu, Kyoto, Japan). Color formation in specimens with dithiothreitol was compared with color formation in the blank tubes, and the results were expressed as absorbance units. Serum levels of asymmetric dimethylarginine were detected with a commercially available enzyme-linked immunosorbent assay kit. Measurement was performed using a computer-based enzyme-linked immunosorbent assay reader (ELx 800 Universal Microplate Reader, Biotek Instruments, Winooski, Vermont) with a wavelength of 405 nm.

Outcome Parameters

Demographic data (age, sex, body mass index), polysomnographic indices (AHI, mean oxygen saturation, time for arterial oxygen saturation [SpO2] <90%, number of apnea), and biochemical parameters (serum levels of asymmetric dimethylarginine and ischemia-modified albumin) were noted and compared in 3 groups. Moreover, correlations of biochemical parameters to demographic and polysomnographic variables were sought.

Statistical Analysis

Data were analyzed using SPSS Statistics 20.0 for Windows (IBM, Armonk, New York). Normal distribution of variables was assessed with the Kolmogorov-Smirnov test. Parametric methods were used in the analysis of the variations that have normal distribution, and nonparametric methods were used in the analysis of the variations that do not have normal distribution. Correlation between variables with normal distribution was evaluated with the Pearson correlation test, whereas Spearman's rho test was preferred if at least one of the variables did not exhibit normal distribution. Comparison of groups in terms of variables with normal distribution was implemented with one-way analysis of variance. Variables without normal distribution were evaluated with the Kruskal-Wallis test. Homogeneity of variances of groups was analyzed with the Levene test. For groups with variables with homogeneous variances, the Duncan test was used. However, the Tamhane test was preferred for variables of groups with non-homogeneous variances. Quantitative variables were expressed as mean, SD, minimum, and maximum values. CI was set at 95%, and all differences associated with a P value of <.05 were considered statistically significant.

Results

A comparison of variables under investigation in the 3 groups is shown in Table 1. Distribution of male/female subjects was similar in the 3 groups (P = .58). Those in Group 1 were younger than those in Groups 2 and 3 (P < .001), but there was no age difference between those in Groups 2 and 3 (P = .99). The body mass index of Group 1 was remarkably lower than those of Groups 2 and 3 (P = .008). Serum levels of ischemia-modified albumin were significantly higher in Groups 2 and 3 (P = .001). Levels of serum ischemia-modified albumin in the 3 groups are shown in Figure 1. Mean oxygen saturation of Group 3 was notably lower than that of Groups 1 and 2 (P < .001), whereas times for SpO2 <90% were statistically significantly different from each other in all 3 groups (P < .001). Serum levels of asymmetric dimethylarginine in Group 3 were notably higher than that in Group 1 (P = .027). Levels of serum asymmetric dimethylarginine in the 3 groups are demonstrated in Figure 2. Correlation analysis revealed that only serum levels of ischemia-modified albumin were correlated positively with AHI and time for SpO2 <90% values (r = 0.298, P = .008 and r = 0.458, P = .001). In subjects with OSA, there was no correlation between ischemia-modified albumin and asymmetric dimethylarginine (r = 0.75, P = .51).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1.

Comparison of Demographic, Polysomnographic, and Biochemical Variables Under Investigation in the 3 Subject Groups

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.

Serum ischemia-modified albumin (IMA) levels in the 3 subject groups. P = .001.

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.

Serum asymmetric dimethylarginine (ADMA) levels in the 3 subject groups. P = .027.

Discussion

The present study was carried out to investigate whether serum levels of asymmetric dimethylarginine and ischemia-modified albumin were altered in OSA and to determine whether levels of these biomarkers were correlated with demographic parameters or polysomnographic indices. Our results have shown that serum levels of ischemia-modified albumin and asymmetric dimethylarginine were significantly higher in subjects with OSA, and levels of ischemia-modified albumin were correlated positively with AHI and values for time SpO2 <90%.

Obstructive sleep apnea is reported to be a risk factor for cardiovascular morbidity due to the hazardous outcomes of oxidative stress, vascular endothelial dysfunction, and inflammation.15–18 Efforts made to clarify the link between OSA and cardiovascular disorders have pointed to endothelial dysfunction as a key step linking these 2 pathological processes.16–18 Chronic intermittent hypoxia may have reverse effects on endothelial function, reducing endothelial nitric oxide bioavailability and amplifying the effects of oxidative stress and inflammation.19,20 Increased levels of adhesion molecules and hypercoagulability enhance the vascular damage, leading to the occurrence of cardiovascular morbidity in OSA.19,20

Asymmetric dimethylarginine levels were increased under hypoxic conditions.9 In addition to oxidative stress, elevated asymmetric dimethylarginine levels are substantial factors leading to impairment of nitric oxide availability and diminished endothelium-dependent vasodilatation, and their increased levels have been reported in cardiovascular disease.21,22 Increased plasma concentration of asymmetric dimethylarginine is associated with hypertension, pulmonary hypertension, hypercholesterolemia, and severe peripheral artery occlusive diseases.15,17,23,24 These findings suggest that asymmetric dimethylarginine is responsible for endothelial dysfunction. Barceló et al25 assessed plasma asymmetric dimethylarginine in subjects with OSA and found it to be significantly higher in these subjects irrespective of the presence of further cardiovascular risk. Following CPAP therapy with significant reduction of intermittent hypoxemia, the levels of asymmetric dimethylarginine can be decreased.15

Ischemia-modified albumin may indicate underlying subclinical disease or vascular dysfunction.26 Increased levels of ischemia-modified albumin may serve as a nonspecific risk marker for evaluation of the oxidative stress status and atherosclerotic burden.13,27,28 Increased production of free radicals and pro-inflammatory cytokines in OSA are sources of the oxidative damage at the cellular and subcellular levels.18 Yang et al13 suggested that increased levels of ischemia-modified albumin in subjects with OSA may result from increased oxidative stress. Ischemia-modified albumin is produced in response to ischemic stresses, such as hypoxia and acidosis. The attenuation of ischemia-modified albumin frequently indicates an acute ischemic event like acute coronary syndrome, a pulmonary embolism, or acute ischemic stroke.29–31 Similarly, our results demonstrated that serum ischemia-modified albumin levels were elevated significantly in all subjects with OSA. Correlation of ischemia-modified albumin levels with oxygen desaturation index and AHI is interesting, since it suggests that indicators of systemic inflammation may reflect the link between OSA and cardiovascular morbidity. Further trials must be carried out to investigate the predictive potential of ischemia-modified albumin for severities of oxygen desaturation and OSA.

A study done by Verma at al.32 on the role of ischemia-modified albumin in pathogenesis of hyperthyroidism has indicated that elevated ischemia-modified albumin is associated with increased production of asymmetric dimethylarginine, which acts as an inhibitor of nitric-oxide synthase. This may account for ischemic injury caused by the reduction of nitric oxide synthesis. We could not find a correlation between ischemia-modified albumin and asymmetric dimethylarginine in the subjects with OSA.

Conclusions

Ischemia-modified albumin and asymmetric dimethylarginine were significantly higher in subjects with OSA. Furthermore, ischemia-modified albumin was associated with severity of OSA syndrome defined by AHI and severity of oxygen desaturation. Results of the current study have shown that serum levels of ischemia-modified albumin and asymmetric dimethylarginine may be altered in OSA, reflecting the deterioration of vascular endothelial function. Understanding the clinical importance of these potential biomarkers and their utility in terms of diagnosis, follow-up, and treatment will necessitate further clinical trials on larger series.

Footnotes

  • Correspondence: Aysel Sunnetcioglu MD, Department of Chest Diseases, Yuzuncu Yil University, Faculty of Medicine, Van, Turkey. E-mail: izciaysel{at}mynet.com.
  • The authors have disclosed no conflicts of interest.

  • Copyright © 2016 by Daedalus Enterprises

References

  1. 1.↵
    1. Berry RB,
    2. Brooks R,
    3. Gamaldo CE,
    4. Harding SM,
    5. Lloyd RM,
    6. Marcus CL,
    7. et al
    . The AASM manual for the scoring of sleep and associated events: terminology and technical specifications, version 2.0.2. www.aasmnet.org. Darien, IL: American Academy of Sleep Medicine, 2013.
  2. 2.↵
    1. Strohl KP,
    2. Brown DB,
    3. Collop N,
    4. George C,
    5. Grunstein R,
    6. Han F,
    7. et al
    . An official American Thoracic Society Clinical Practice Guideline: sleep apnea, sleepiness and driving risk in noncommercial drivers: an update of a 1994 statement. Am J Respir Crit Care Med 2013;187(11):1259–1266.
    OpenUrlCrossRefPubMed
  3. 3.
    1. Pack AI,
    2. Gislason T
    . Obstructive sleep apnea and cardiovascular disease: a perspective and future directions. Prog Cardiovasc Dis 2009;51(5):434–451.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bradley TD,
    2. Floras JS
    . Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009;373(9657):82–93.
    OpenUrlCrossRefPubMed
  5. 5.
    1. Chowdhury M,
    2. Adams S,
    3. Whellan DJ
    . Sleep-disordered breathing and heart failure: focus on obstructive sleep apnea and treatment with continuous positive airway pressure. J Card Fail 2010;16(2):164–174.
    OpenUrlPubMed
  6. 6.↵
    1. Bordier P
    . Sleep apnoea in patients with heart failure: part II: therapy. Arch Cardiovasc Dis 2009;102(10):711–720.
    OpenUrlPubMed
  7. 7.↵
    1. Bhadriraju S,
    2. Kemp CR Jr.,
    3. Cheruvu M,
    4. Bhdriraju S
    . Sleep apnea syndrome: implications on cardiovascular diseases. Crit Pathw Cardiol 2008;7(4):248–253.
    OpenUrlPubMed
  8. 8.↵
    1. Carlson JT,
    2. Rångemark C,
    3. Hedner JA
    . Attenuated endothelium dependent vascular relaxation in subjects with sleep apnoea. J Hypertens 1996;14(5):577–584.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Yildirim AO,
    2. Bulau P,
    3. Zakrzewicz D,
    4. Kitowska KE,
    5. Weissmann N,
    6. Grimminger F,
    7. et al
    . Increased protein arginine methylation in chronic hypoxia: role of protein arginine methyltransferases. Am J Respir Cell Mol Biol 2006;35(4):436–443.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Oettl K,
    2. Stauber RE
    . Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol 2007;151(5):580–590.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Sbarouni E,
    2. Georgiadou P,
    3. Kremastinos DT,
    4. Voudris V
    . Ischemia modified albumin: is this marker of ischemia ready for prime time use? Hellenic J Cardiol 2008;49(4):260–266.
    OpenUrlPubMed
  12. 12.↵
    1. Dean RT,
    2. Wilcox I
    . Possible atherogenic effects of hypoxia during obstructive sleep apnea. Sleep 1993;16(8 Suppl):S15–S21; discussion S21-S22.
    OpenUrlPubMed
  13. 13.↵
    1. Yang LX,
    2. Ma SG,
    3. Liu H,
    4. Xu W
    . Influence of obstructive sleep apnea on serum butyrylcholinesterase activity and ischemia-modified albumin levels. Clinics 2013;68(7):968–973.
    OpenUrlPubMed
  14. 14.↵
    1. Bar-Or D,
    2. Lau E,
    3. Winkler JV
    . A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia a preliminary report. J Emerg Med 2000;19(4):311–315.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Ohike Y,
    2. Kozaki K,
    3. Iijima K,
    4. Eto M,
    5. Kojima T,
    6. Ohga E,
    7. et al
    . Amelioration of vascular endothelial dysfunction in obstructive sleep apnea syndrome by nasal continuous positive airway pressure–possible involvement of nitric oxide and asymmetric NG, NG-dimethylarginine. Circ J 2005;69(2):221–226.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Gozal D,
    2. Kheirandish-Gozal L,
    3. Serpero LD,
    4. Sans Capdevila O,
    5. Dayyat E
    . Obstructive sleep apnea and endothelial function in school-aged nonobese children: effect of adenotonsillectomy. Circulation 2007;116(20):2307–2314.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Barceló A,
    2. Piérola J,
    3. de la Peña M,
    4. Esquinas C,
    5. Sanchez-de la Torre M,
    6. Ayllón O,
    7. et al
    . Day-night variations in endothelial dysfunction markers and haemostatic factors in sleep apnoea. Eur Respir J 2012;39(4):913–918.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Hoyos CM,
    2. Melehan KL,
    3. Liu PY,
    4. Grunstein RR,
    5. Phillips CL
    . Does obstructive sleep apnea cause endothelial dysfunction? a critical review of the literature. Sleep Med Rev 2015;20:15–26.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Lavie L,
    2. Hefetz A,
    3. Luboshitzky R,
    4. Lavie P
    . Plasma levels of nitric oxide and l-arginine in sleep apnea subjects: effects of nCPAP treatment. J Mol Neurosci 2003;21(1):57–63.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Lavie L
    . Oxidative stress inflammation and endothelial dysfunction in obstructive sleep apnea. Front Biosci (Elite Ed) 2012;4(1):1391–1403.
    OpenUrlPubMed
  21. 21.↵
    1. Ozkan Y,
    2. Ozkan E,
    3. Simşek B
    . Plasma total homocysteine and cysteine levels as cardiovascular risk factors in coronary heart disease. Int J Cardiol 2002;82(3):269–277.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Valkonen VP,
    2. Paiva H,
    3. Salonen JT,
    4. Lakka TA,
    5. Lehtimäki T,
    6. Laakso J,
    7. Laaksonen R
    . Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet 2001;358(9299):2127–2138.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Ozkan Y,
    2. Firat H,
    3. Simşek B,
    4. Torun M,
    5. Yardim-Akaydin S
    . Circulating nitric oxide (NO), asymmetric dimethylarginine (ADMA), homocysteine and oxidative status in obstructive sleep apnea-hypopnea syndrome (OSAHS). Sleep Breath 2008;12(2):149–154.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Yüksel M,
    2. Okur HK,
    3. Pelin Z,
    4. Öğünç AV,
    5. Öztürk L
    . Arginase activity and nitric oxide levels in subjects with obstructive sleep apnea syndrome. Clinics 2014;69(4):247–252.
    OpenUrlPubMed
  25. 25.↵
    1. Barceló A,
    2. de la Peña M,
    3. Ayllón O,
    4. Vega-Agapito MV,
    5. Piérola J,
    6. Pérez G,
    7. et al
    . Increased plasma levels of asymmetric dimethylarginine and soluble CD40 ligand in subjects with sleep apnea. Respiration 2009;77(1):85–90.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Borderie D,
    2. Allanore Y,
    3. Meune C,
    4. Devaux JY,
    5. Ekindjian OG,
    6. Kahan A
    . High ischemia-modified albumin concentration reflects oxidative stress but not myocardial involvement in systemic sclerosis. Clin Chem 2004;50(11):2190–2193.
    OpenUrlFREE Full Text
  27. 27.↵
    1. Turedi S,
    2. Cinar O,
    3. Yavuz I,
    4. Mentese A,
    5. Gunduz A,
    6. Karahan SC,
    7. et al
    . Differences in ischemia-modified albumin levels between end stage renal disease subjects and the normal population. J Nephrol 2010;23(3):335–340.
    OpenUrlPubMed
  28. 28.↵
    1. Ma SG,
    2. Wei CL,
    3. Hong B,
    4. Yu WN
    . Ischemia-modified albumin in type 2 diabetic subjects with and without peripheral arterial disease. Clinics 2011;66(10):1677–1680.
    OpenUrlPubMed
  29. 29.↵
    1. Pantazopoulos I,
    2. Papadimitriou L,
    3. Dontas I,
    4. Demestiha T,
    5. Iakovidou N,
    6. Xanthos T
    . Ischaemia modified albumin in the diagnosis of acute coronary syndromes. Resuscitation 2009;80(3):306–310.
    OpenUrlPubMed
  30. 30.
    1. Turedi S,
    2. Gunduz A,
    3. Mentese A,
    4. Topbas M,
    5. Karahan SC,
    6. Yeniocak S,
    7. et al
    . The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Respir Res 2008;9:49.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Abboud H,
    2. Labreuche J,
    3. Meseguer E,
    4. Lavallee PC,
    5. Simon O,
    6. Olivot JM,
    7. et al
    . Ischemia-modified albumin in acute stroke. Cerebrovasc Dis 2007;23(2):216–220.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Verma M,
    2. Dahiya K,
    3. Ghalaut VS,
    4. Soni A,
    5. Singh J,
    6. Dhupper V
    . Comparative study of ischemia modified albumin and nitric oxide in hyperthyroidism. J Invest Biochem 2014;3(1):17–20.
    OpenUrl
PreviousNext
Back to top

In this issue

Respiratory Care: 61 (8)
Respiratory Care
Vol. 61, Issue 8
1 Aug 2016
  • Table of Contents
  • Table of Contents (PDF)
  • Cover (PDF)
  • Index by author

 

Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on American Association for Respiratory Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Increased Asymmetric Dimethylarginine and Ischemia-Modified Albumin Levels in Obstructive Sleep Apnea
(Your Name) has sent you a message from American Association for Respiratory Care
(Your Name) thought you would like to see the American Association for Respiratory Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Increased Asymmetric Dimethylarginine and Ischemia-Modified Albumin Levels in Obstructive Sleep Apnea
Aysel Sunnetcioglu, Selvi Asker, Hamit Hakan Alp, Hulya Gunbatar
Respiratory Care Aug 2016, 61 (8) 1038-1043; DOI: 10.4187/respcare.04472

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Increased Asymmetric Dimethylarginine and Ischemia-Modified Albumin Levels in Obstructive Sleep Apnea
Aysel Sunnetcioglu, Selvi Asker, Hamit Hakan Alp, Hulya Gunbatar
Respiratory Care Aug 2016, 61 (8) 1038-1043; DOI: 10.4187/respcare.04472
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

Keywords

  • obstructive sleep apnea
  • asymmetric dimethylarginine
  • ischemia modified albumin

Info For

  • Subscribers
  • Institutions
  • Advertisers

About Us

  • About the Journal
  • Editorial Board

AARC

  • Membership
  • Meetings
  • Clinical Practice Guidelines

More

  • Contact Us
  • RSS
American Association for Respiratory Care

Print ISSN: 0020-1324        Online ISSN: 1943-3654

© Daedalus Enterprises, Inc.

Powered by HighWire